Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. Rohaan MW, et al. Among authors: stevense den boer mam. N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. N Engl J Med. 2022. PMID: 36477031 Clinical Trial.
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
van Zeijl MCT, van Breeschoten J, de Wreede LC, Wouters MWJM, Hilarius DL, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Suijkerbuijk KPM, Haanen JBAG, van den Eertwegh AJM. van Zeijl MCT, et al. Among authors: stevense den boer ma. J Immunother. 2023 Jun 1;46(5):197-204. doi: 10.1097/CJI.0000000000000468. Epub 2023 Apr 28. J Immunother. 2023. PMID: 37103470 Clinical Trial.
Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.
Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van Eijs MJM, de Groot JB, Hospers GAP, Kapiteijn E, de Meza M, Piersma D, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Suijkerbuijk KPM, Blokx WAM. Van Not OJ, et al. Among authors: stevense den boer m. Eur J Cancer. 2023 Jun;186:27-37. doi: 10.1016/j.ejca.2023.03.009. Epub 2023 Mar 16. Eur J Cancer. 2023. PMID: 37023588 Free article.
A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.
van Not OJ, Wind TT, Ismail RK, Bhattacharya A, Jalving M, Blank CU, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Haanen JB, Kapiteijn E, Bloem M, Piersma D, van Rijn RS, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM, Fehrmann RSN, Hospers GAP. van Not OJ, et al. Among authors: stevense den boer m. Cancers (Basel). 2023 May 26;15(11):2922. doi: 10.3390/cancers15112922. Cancers (Basel). 2023. PMID: 37296885 Free PMC article.
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
van Not OJ, Verheijden RJ, van den Eertwegh AJM, Haanen JBAG, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JB, Hospers GAP, Kamphuis AM, Kapiteijn E, May AM, de Meza MM, Piersma D, van Rijn R, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Blokx WAM, Wouters MJM, Suijkerbuijk KPM. van Not OJ, et al. Among authors: stevense den boer ma. JAMA Oncol. 2022 Dec 1;8(12):1794-1801. doi: 10.1001/jamaoncol.2022.5041. JAMA Oncol. 2022. PMID: 36301521 Free PMC article.
A prediction model for response to immune checkpoint inhibition in advanced melanoma.
van Duin IAJ, Verheijden RJ, van Diest PJ, Blokx WAM, El-Sharouni MA, Verhoeff JJC, Leiner T, van den Eertwegh AJM, de Groot JWB, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Stevense-den Boer MAM, Boers-Sonderen MJ, Kapiteijn E, Suijkerbuijk KPM, Elias SG. van Duin IAJ, et al. Among authors: stevense den boer mam. Int J Cancer. 2024 May 15;154(10):1760-1771. doi: 10.1002/ijc.34853. Epub 2024 Jan 31. Int J Cancer. 2024. PMID: 38296842
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.
van Not OJ, van den Eertwegh AJM, Haanen JB, Blank CU, Aarts MJB, van Breeschoten J, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Ismail RK, Kapiteijn E, Bloem M, De Meza MM, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokx WAM, Wouters MWJM, Suijkerbuijk KPM. van Not OJ, et al. Among authors: stevense den boer mam. EClinicalMedicine. 2024 Feb 12;69:102485. doi: 10.1016/j.eclinm.2024.102485. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38370537 Free PMC article.
BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JWWB, Hospers GAP, Kapiteijn E, Bloem M, Piersma D, Stevense-den Boer M, Verheijden RJ, van der Veldt AAM, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM. Van Not OJ, et al. Among authors: stevense den boer m. Cancer. 2024 May 1;130(9):1673-1683. doi: 10.1002/cncr.35178. Epub 2024 Jan 10. Cancer. 2024. PMID: 38198485
The unfavorable effects of COVID-19 on Dutch advanced melanoma care.
van Not OJ, van Breeschoten J, van den Eertwegh AJM, Hilarius DL, De Meza MM, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Ismail RK, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokx WAM, Suijkerbuijk KPM, Wouters MWJM. van Not OJ, et al. Among authors: stevense den boer mam. Int J Cancer. 2022 Mar 1;150(5):816-824. doi: 10.1002/ijc.33833. Epub 2021 Oct 22. Int J Cancer. 2022. PMID: 34605003 Free PMC article.
Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.
van Not OJ, de Meza MM, van den Eertwegh AJM, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, van Breeschoten J, de Groot JB, Hospers GAP, Ismail RK, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Bonenkamp HJ, Boers-Sonderen MJ, Blokx WAM, Wouters MWJM, Suijkerbuijk KPM. van Not OJ, et al. Among authors: stevense den boer mam. Eur J Cancer. 2022 May;167:70-80. doi: 10.1016/j.ejca.2022.02.026. Epub 2022 Apr 5. Eur J Cancer. 2022. PMID: 35395553 Free article.
17 results